Review Mortgage Lenders

Acura Mortgage

Camaro puts aggressive Acura back in its place

100% stock (right down to the paper air filter) 1993 LT1 powered Camaro automatic, out for a cruise after a couple base Dyno pulls, and ran into ...

Reviewing Fortress Biotech (FBIO) and Acura Pharmaceuticals ...

Fortress Biotech Company Profile

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.

East Liberty Honda plant showcases new Acura RDX

EAST LIBERTY — The East Liberty Honda Auto plant showcased its new 2019 Acura RDX Tuesday, the first of a new generation of Acura products built around Acura’s Precision Crafted Performance.

The new five-passenger luxury SUV is equipped with a 2.0-liter VTEC Turbo engine with 272 horsepower, a 10-speed automatic transmission (10AT), touch screen entertainment controls, a ultra-wide panoramic moonroof, a multi layer paint system, and premium exterior color options.

The new model is the first RDX to be designed and developed in America. The Acura design Studio in Los Angeles, California designed came up with the design and the North American R&D in Raymond, Ohio developed it.

The price of the vehicle is yet to be discussed but is expected to be on the market by June of 2018, according to Scott Ruhl, Engineering Project Leader.

This new product line was made possible by the East Liberty plant’s new capital $54 million investment of new technologies and processes. The VTEC turbo engine was produced at the Anna engine plant and the 10-speed automatic transmission was produced at the transmission plant in Tallapoosa, Georgia. The three plants worked on the project for four years.